Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.

被引：0
|
作者：
Maruzzo, Marco
Basso, Umberto
Diminutto, Alberto
De Giorgi, Ugo
Fratino, Lucia
Lo Re, Giovanni
D'Angelo, Alessandro
Donini, Maddalena
Verderame, Francesco
Ratta, Raffaele
Procopio, Giuseppe
Campadelli, Enrico
Massari, Francesco
Gasparro, Donatello
Macrini, Sveva
Messina, Caterina
Giordano, Monica
Maines, Francesca
Zagonel, Vittorina
Caffo, Orazio
机构：
[1] IRCCS, IOV, Med Oncol 1, Padua, Italy
[2] IRCCS, Ist Oncol Veneto, Padua, Italy
[3] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Natl Canc Ctr CRO, Aviano, Italy
[5] Santa Maria Degli Angeli Gen Hosp, Pordenone, Italy
[6] Civil Hosp, Taormina, Italy
[7] Ist Ospitalieri Cremona, Cremona, Italy
[8] Cervello Hosp, Palermo, Italy
[9] Unicampus Univ, Rome, Italy
[10] Ist Nazl Tumori, Fdn IRCCS, Oncol Unit 1, I-20133 Milan, Italy
[11] Civil Hosp, Lugo Di Romagna, Italy
[12] Univ Verona, Med Oncol, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[13] Univ Hosp Parma, Parma, Italy
[14] Univ Hosp, Udine, Italy
[15] Pope John Paul XXIII Hosp, Med Oncol Unit, Bergamo, Italy
[16] Santa Anna Hosp, Como, Italy
[17] Santa Chiara Hosp, Trento, Italy
[18] IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [22] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [23] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [25] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [27] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [29] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN
    Shibahara, H.
    Shiroiwa, T.
    Nakamura, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A416
12345